Cline Scientific's CEO is taking a break from the position of CEO at his own request
Cline Scientific AB (publ) ("Cline" or the "Company") CEO Patrik Sundh has, at his own request, informed the Company's board that he has decided to take a break from the position of CEO until the investigation into suspected market manipulation is complete. The Board of the Company has appointed Hanne Evenbratt as Acting CEO during this time.
In order not to influence the Company, CEO Patrik Sundh has stated to the board that as of today, May 8, he intends to take a break from his position as CEO until it is clear what the preliminary investigation shows. The board has granted this request and appointed Vice President Hanne Evenbratt as Acting CEO during this time. Hanne takes office immediately.
"Hanne has been part of Cline's journey since an early stage and is very familiar with the company and its various projects. We believe that this solution is clearly the best in the situation that has arisen and hope that Patrik's situation is quickly resolved in the best way without harm to him or Cline."
Johan Bjurquist, Chairman of the Board
Bio Hanne Evenbratt
Hanne has completed a doctorate in pharmaceutical technology at Chalmers Institute of Technology in Gothenburg. Her dissertation work included research collaborations with groups within the University of Gothenburg, Stanford University and the University of Texas. She has also collaborated with Sahlgrenska University Hospital and has been employed at Astra Zeneca within, among other things, GMP production. Hanne was the third person to be hired at Cline and has been the main person responsible for product development in the Company since 2015.
Cline Scientific AB (publ) ("Cline" or the "Company") CEO Patrik Sundh has, at his own request, informed the Company's board that he has decided to take a break from the CEO position until the investigation into suspected market manipulation is complete. The board of the Company has appointed Hanne Evenbratt as Acting CEO during this time.
In order not to influence the Company, CEO Patrik Sundh has stated to the board that as of today, May 8, he intends to take a break from his position as CEO until it is clear what the preliminary investigation that has begun shows. The board has granted this request and appointed Vice President Hanne Evenbratt as Acting CEO during this time. Hanne takes office immediately.
The company is listed on the Nasdaq First North Growth Market. Redeye AB is Cline Scientific's Certified Adviser.
This information is information that Cline Scientific is required to disclose pursuant to the EU Market Abuse Regulation. The information was submitted for publication by the contact person set out above, at 8:59 CEST on 8 May 2023.
For more information, please contact:
Johan Bjurquist, Chairman of the board
Phone: 073-747 1990
Cline Scientific AB (publ) Phone: 031-387 55 55
Argongatan 2 C Email: info@clinescientific.com
431 53 MÖLNDAL Website: www.clinescientific.com
About Cline Scientific
Cline Scientific develops advanced cancer diagnostics and regenerative medicine treatments. Cline’s unique patented surface nanotechnology provides solutions to critical challenges for cell-based products and process in Life Science. Cline is driving two projects through to a clinical stage, StemCART - a stem cell therapy for joint repair, and CellRACE- a cancer diagnostic to predict metastasis.